Skip to content
Trial Eligibility
Menu

Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms

NCT07136415

This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .

Summary

The goal of this clinical trial is to learn how three current insomnia therapies (trazodone, daridorexant, cognitive behavioral therapy for insomnia) compare with each other in peri- and post-menopausal women. It will also learn about the safety of the treatments. The main questions it aims to answer are: Which commonly used insomnia therapies are most effective and safe for improving insomnia symptoms in peri- and post-menopausal people?

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Menopausal Women
  • Insomnia

Eligibility basics and study details

Study type
Interventional
Phase
Phase 4
Ages
40 to 62 years
Sex
Female
Healthy volunteers
Not accepted
Sponsor
Brigham and Women's Hospital
Last updated on ClinicalTrials.gov
June 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Massachusetts · 1

  • Brigham and Women's Hospital · Boston, MA

Michigan · 1

  • Henry Ford Medical Center · Novi, MI

Pennsylvania · 1

  • University of Pittsburgh Medical Center · Pittsburgh, PA

Utah · 1

  • University of Utah · Salt Lake City, UT

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.